At this ACR Convergence 2025 session, experts discussed disease management considerations to optimize outcomes in pregnant patients with SLE.
Metabolic Syndrome & RA Treatment Response
Research from Baker et al. demonstrated a strong association between the presence of metabolic syndrome and lower response rates to advanced therapies in patients with RA.
Expert Guidance from the ACR/ARP Access in Rheumatology Meeting
ACR/ARP Access in Rheumatology—As part of ACR Education Exchange 2023, the ACR/ARP Access in Rheumatology meeting addressed some of the major challenges in coverage and payment that U.S. rheumatology practices face. Speakers included rheumatologists, rheumatology professionals, office managers and CEOs. The first section, Thriving, Not Just Surviving—Keeping Your Rheumatology Practice Solvent, focused on financial management…
The Complexity of SLE Drug Research
PHILADELPHIA—On Saturday, Nov. 12, at ACR Convergence 2022, Joan T. Merrill, MD, director of clinical projects in the Arthritis & Clinical Immunology Program at the Oklahoma Medical Research Foundation in Oklahoma City, gave a presentation on the future of drug development and treatments for systemic lupus erythematosus (SLE). She described how an in-depth understanding of…
Treatment Factors to Consider in Patients with JIA
Weighing treatment options and adjusting them to meet the needs of patients with JIA is a complicated process. Experts discussed factors influencing treatment options, optimizing treatment doses and possibilities for treatment withdrawal for these patients.
Insights into the Symptom Heterogeneity of Post-Treatment Lyme Disease
New research into the symptom heterogeneity of patients with post-treatment Lyme disease may serve as a framework to create targeted interventions or novel treatments for these patients.
The Care & Treatment of Myositis: Creatinine Kinase Level Isn’t Gospel & Other Recommendations
During a session at the 2019 ACR/ARP Annual Meeting, Lisa Christopher-Stine, MD, MPH, provided valuable recommendations and practical insights into the care and treatment of myositis patients…
Insight into Clinical Trials for Lupus
Research into lupus treatments suffered a setback after the failure of anifrolumab in clinical trials. However, during the 2019 ACR State-of-the-Art Clinical Symposium, Richard Furie, MD, outlined the possibilities of multiple new lupus therapies under investigation…
Gene Therapy for OA
Background & objective: One of the major challenges in the treatment of chronic joint diseases, such as osteoarthritis (OA), is the need to provide sustained bioavailability of a therapeutic agent within the joint. Systemically administered drugs cannot sufficiently reach the synovial space, and intra-articularly injected agents are cleared from the joint fluid rapidly by the…
Promising Avenues in Myositis: Research Targets Disease Specificity
AMSTERDAM—Research in myositis treatments is beginning to find its way, with investigators pursuing avenues special to the disease so therapy for patients may no longer involve piggybacking on existing treatments for other illnesses, an expert said at EULAR: the Annual European Congress of Rheumatology. “Finally, in myositis there are targets being investigated that are more…
- 1
- 2
- 3
- …
- 41
- Next Page »